LANCASTER, Calif. – Simulations Plus, Inc. (NASDAQ:SLP – News), a leading provider of simulation and modeling software for pharmaceutical discovery and development, has announced the launch of its MedChem Studio™ software for drug discovery.

Dr. David Miller, team leader for Discovery Cheminformatics at Simulations Plus, said, “MedChem Studio is the result of a continuous evolution of our ClassPharmer™ software, with new capabilities added that have taken it beyond the pure data mining tool that ClassPharmer was and transformed it into a platform that combines data mining and, when integrated with ADMET Predictor™, powerful new molecule design capabilities. The name has been changed to reflect the much-expanded capabilities of this powerful software.”

MedChem Studio Version 1.0 incorporates:

The powerful class generation capabilities of earlier ClassPharmer versions

A variety of intelligent algorithms for rapid generation of new molecular structures

Convenient integration with ADMET Predictor™ 5.0 for best-in-class property predictions

Numerous new graphical presentations that provide greater insight into data

Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: “Medicinal chemists have a very challenging job – so challenging that many spend their entire careers without ever creating a successful drug. The high failure rate of molecules that were designed only for binding to a particular target (“activity”), but that did not also have all of the many other properties needed to become approved drugs, has been largely a result of the traditional approach of focusing on activity while ignoring many other required properties. This has primarily been because chemists were not able to monitor how the other properties were changing as they sought better activity. Now, with MedChem Studio and ADMET Predictor, chemists can ‘see’ the effects of modifying molecular structures not only on activity, but also on many additional key properties, enabling them to modify a structure to simultaneously optimize activity and other properties. MedChem Studio combined with ADMET Predictor helps chemists design new molecules with a multidimensional view of the many properties that are required for a molecule to become a drug. We believe this represents the next-generation approach to molecule design.”

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. The Company’s Words+, Inc., wholly owned subsidiary provides augmentative communication systems and other technologies for persons with disabilities. Simulations Plus is headquartered in Southern California. For more information, visit our web site at www.simulations-plus.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the Securities and Exchange Commission.